InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use

D. Singh; G. J. Criner; M. T. Dransfield; D. M. G. Halpin; M. K. Han; C. E. Jones; S. Kilbride; P. Lange; D. A. Lomas; F. J. Martinez; S. J. Pascoe; R. A. Wise; D. A. Lipson

InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use

D. Singh, G. J. Criner, M. T. Dransfield, D. M. G. Halpin, M. K. Han, C. E. Jones, S. Kilbride, P. Lange, D. A. Lomas, F. J. Martinez, S. J. Pascoe, R. A. Wise, D. A. Lipson

Genomforskning og Molekylær Biomedicin

Originalsprog	Engelsk
Artikelnummer	A24
Tidsskrift	American Journal of Respiratory and Critical Care Medicine
Vol/bind	199
Udgave nummer	A1116
ISSN	1073-449X
Status	Udgivet - 2019

Adgang til dokumentet

https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1116

Citationsformater

Singh, D., Criner, G. J., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Jones, C. E., Kilbride, S., Lange, P., Lomas, D. A., Martinez, F. J., Pascoe, S. J., Wise, R. A., & Lipson, D. A. (2019). InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use. American Journal of Respiratory and Critical Care Medicine, 199(A1116 ), Artikel A24. https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1116

InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use. / Singh, D.; Criner, G. J.; Dransfield, M. T. et al.
I: American Journal of Respiratory and Critical Care Medicine, Bind 199, Nr. A1116 , A24, 2019.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Singh, D, Criner, GJ, Dransfield, MT, Halpin, DMG, Han, MK, Jones, CE, Kilbride, S, Lange, P, Lomas, DA, Martinez, FJ, Pascoe, SJ, Wise, RA & Lipson, DA 2019, 'InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use', American Journal of Respiratory and Critical Care Medicine, bind 199, nr. A1116 , A24. <https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1116>

Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE et al. InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use. American Journal of Respiratory and Critical Care Medicine. 2019;199(A1116 ):A24.

Singh, D. ; Criner, G. J. ; Dransfield, M. T. et al. / InforMing the PAthway of COPD Treatment (The IMPACT Study) : Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use. I: American Journal of Respiratory and Critical Care Medicine. 2019 ; Bind 199, Nr. A1116 .

@article{35010ec1ca7c46e9aa2249f691332e0a,

title = "InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use",

author = "D. Singh and Criner, {G. J.} and Dransfield, {M. T.} and Halpin, {D. M. G.} and Han, {M. K.} and Jones, {C. E.} and S. Kilbride and P. Lange and Lomas, {D. A.} and Martinez, {F. J.} and Pascoe, {S. J.} and Wise, {R. A.} and Lipson, {D. A.}",

year = "2019",

language = "English",

volume = "199",

journal = "American Journal of Respiratory and Critical Care Medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "A1116 ",

}

TY - ABST

T1 - InforMing the PAthway of COPD Treatment (The IMPACT Study)

T2 - Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use

AU - Singh, D.

AU - Criner, G. J.

AU - Dransfield, M. T.

AU - Halpin, D. M. G.

AU - Han, M. K.

AU - Jones, C. E.

AU - Kilbride, S.

AU - Lange, P.

AU - Lomas, D. A.

AU - Martinez, F. J.

AU - Pascoe, S. J.

AU - Wise, R. A.

AU - Lipson, D. A.

PY - 2019

Y1 - 2019

M3 - Conference abstract in journal

SN - 1073-449X

VL - 199

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

IS - A1116

M1 - A24

ER -